• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

18
13
9
8
6

COUNTRY

6
2
2
1
1

CATEGORIES

  • 25
  • 10
  • 6
  • 4
  • 4
  • 4
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

14
16
25
60

PUBLISHED

1
5
23
60

PRODUCT TYPE

46
14

Search "Eisai: Pipeline, Products, Performance and Potential" returned 60 results.

Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review

Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The...

March 2015
FROM

Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

What Will the Pharma Industry Look Like in 5 Years? There are an estimated 724 projects in development from the top 50 pharmaceutical companies.  Together, they have the potential to add billions...

August 2012
FROM

Pharmaceutical Products of the Future: 50-Company Pipeline Analysis to 2015

What Will The Pharmaceutical Market Look Like in the Next Five Years? In this report, Kalorama has analyzed the late stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies...

July 2010
FROM

Rare Diseases: The Pharmaceutical Landscape and Opportunity Areas

The service oriented and dynamic nature of the healthcare industry has led to the discovery of a plethora of treatment options for a wide range of ailments.However, there are certain diseases, termed...

March 2015
FROM
Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma - Product Thumbnail Image

Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma

Global Pharmaceuticals and biotechnology outlook - Japan Pharma The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi...

January 2013
FROM

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

"Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options" provides in-depth analysis of breast cancer market within the Asia-Pacific...

May 2014
FROM

Venous (Vein) Thrombosis - Pipeline Review, H1 2015

Venous (Vein) Thrombosis - Pipeline Review, H1 2015 Summary This, ‘Venous (Vein) Thrombosis - Pipeline Review, H1 2015’, provides an overview of the Venous (Vein) Thrombosis’s therapeutic pipeline. This...

April 2015
FROM

Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs

The leading business intelligence provider, has released its latest research, '‘Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance...

June 2014
FROM

Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market

The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5 1 billion in 2013 to $7...

July 2014
FROM

Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

This report provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides...

August 2014
FROM

PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis...

February 2013
FROM

PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022”....

February 2013
FROM

PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to...

February 2013
FROM

Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022

Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022”....

February 2013
FROM

PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to...

February 2013
FROM

VX-765 (Epilepsy) - Forecast and Market Analysis to 2022

VX-765 (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “VX-765 (Epilepsy) - Forecast and Market Analysis to 2022”. Epilepsy...

February 2013
FROM

Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022

Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Brivaracetam (Epilepsy) - Forecast and Market Analysis to...

February 2013
FROM
Loading Indicator

Our Clients

Hewlett-Packard Company Microsoft Corporation Philips N.V. SONY Corporation Cypress Semiconductor Corporation Panasonic Corporation